We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
AdAlta is a biotechnology business based in Australia. AdAlta shares (1AD) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. AdAlta has a trailing 12-month revenue of around $4 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.0713 - $0.215 |
|---|---|
| 50-day moving average | $0.0822 |
| 200-day moving average | $0.1073 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.024 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.08
| 1 week (2022-01-14) | 1.27% |
|---|---|
| 1 month (2021-12-22) | -2.44% |
| 3 months (2021-10-22) | -5.88% |
| 6 months (2021-07-22) | -19.19% |
| 1 year (2021-01-22) | -40.74% |
|---|---|
| 2 years (2020-01-22) | -20.00% |
| 3 years (2019-01-22) | -65.44% |
| 5 years (2017-01-20) | -62.30% |
| Revenue TTM | $4 million |
|---|---|
| Gross profit TTM | $3.8 million |
| Return on assets TTM | -42.45% |
| Return on equity TTM | -111.58% |
| Profit margin | -141.26% |
| Book value | 0.026 |
| Market capitalisation | $23.5 million |
TTM: trailing 12 months
We're not expecting AdAlta to pay a dividend over the next 12 months.
Over the last 12 months, AdAlta's shares have ranged in value from as little as $0.0713 up to $0.215. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while AdAlta's is 0.9319. This would suggest that AdAlta's shares are less volatile than average (for this exchange).
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products against various solid tumor antigens. AdAlta Limited was incorporated in 2006 and is based in Bundoora, Australia.
With the total market cap of the crypto sector dropping by a whopping 10% within the last few hours, it seems as though the coming few days could be highly volatile for ETH.
What are the things to watch out for when buying your child's first laptop?
As Russia gets ready to outlaw its local crypto market, BTC could be faced with even greater volatility in the near future.
Heavyweight stars Fancis Ngannou and Cyril Gane headline UFC 270.
Shares in Rio Tinto have climbed more than 15% in the last month.
Here are the 10 biggest movers on the ASX for Friday 21 January 2022.
This leave-in conditioner transformed my unwashed mop into silky locks that would make Rapunzel envious.
Samsung's next flagship S22 phone will be, in its own less than subtle phrasing, "noteworthy".
A fun superhero series, an epic sci-fi and a dark teen drama are among our top picks this week.
